As ASX blue-chip stocks release highly anticipated earnings results, brokers and investors are adjusting their outlooks accordingly. 

Earlier this week, Woolworths Group Ltd (ASX: WOW) released full-year results.

Key results included: 

• Group sales rose 3.6% to $71.54 billion.
• EBITDA before significant items lifted 6.7% to $6.09 billion.
• EBIT before significant items increased 12.7% to $3.11 billion.
• NPAT before significant items jumped 15.4% to $1.60 billion.
• Final fully franked dividend of 52 cents per share, up 15.6% from last year.

Speaking on the results, Woolworths Group CEO Amanda Bardwell said:

The action we have taken in F26 to deliver more value for customers, greater convenience and better execution has improved customer advocacy and sales momentum in our key Australian Food business, particularly in H2. Sales momentum together with strong productivity and cost discipline has delivered solid EBIT growth with an increased contribution from all trading segments.

This prompted a positive reaction from the market, as Woolworths shares have climbed since the announcement. 

However for prospective investors, it is worth noting that Woolworths shares have already climbed over 34% year to date, making it difficult to project big upside. 

What are experts saying?

Yesterday, Woolworths shares closed at $39.55 per share. 

The team at Bell Potter was impressed by the recent results and raised its price target to $42.35. 

This indicates 7% upside. 

Elsewhere, Morgans has a price target of $43.50, indicating a 10% upside. 

However, let’s not forget the recently updated forward dividend yield of 2.38%. 

Taking all of this into consideration, if Woolworths shares were to reach the target set by Bell Potter in the next 12 months, the shares would be worth about $10,707.98, while the estimated dividends would add approximately $238, giving a total value of around $10,945.98, or a 9.46% total return.

If Woolworths shares reached the target set by Morgans, the investment would be worth approximately $10,998.74 plus the estimated $238 dividend, for a total of about $11,236.74, representing a 12.37% total return. 

These calculations assume the 2.38% forward yield remains unchanged and dividends are taken as cash rather than reinvested; actual returns will vary with the share price and dividends paid

Why there might be more upside somewhere else 

While these projections would be a healthy return, there is another ASX consumer staples stock worth considering over the next 12 months. 

Treasury Wine Estates Ltd (ASX: TWE) are trading at around $5.55 per share, but could be set to rise significantly over the next 12 months. 

A recent target from Morgans suggests this could hit $7.30 in the next year. 

From current levels, this indicates over 31% upside. 

This means a $10,000 investment could grow to approximately $13,153 if it met this target. 

The post How much could $10,000 in Woolworths shares be worth in a year? appeared first on The Motley Fool Australia.

More reading

• Do leading brokers rate Woolworths shares as a buy following its results?
• 3 ASX 200 dividend shares that just hiked their payouts
• South32, Woolworths, BHP shares reach 52-week high: Buy, sell or hold?
• Everything you need to know about the Woolworths dividend
• Why Woolworths, Domino’s and DroneShield shares are turning heads on Wednesday

Motley Fool contributor Aaron Bell has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Treasury Wine Estates. The Motley Fool Australia has positions in and has recommended Treasury Wine Estates. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

CSL Ltd (ASX: CSL) shares have staged an extraordinary comeback, jumping 49% in just one month. But after a bruising year, investors face a crucial question: has the turnaround finally arrived, or has the rebound run too far?

Following last week’s FY26 result, brokers have reassessed their forecasts, revealing a striking divide over where CSL shares could head next.

Where do brokers see CSL shares going?

CSL has spent the past few years battling higher costs, operational problems and fading investor confidence. And not every broker believes the recovery is firmly established.

TradingView data shows 10 of 18 analysts rate CSL a hold, while eight have a buy or strong-buy rating. The average 12-month price target is $164.69, below the current share price of around $173.88.

However, the forecasts vary dramatically. The most bullish target sits at $205.22, implying another 18% upside, while the lowest is just $132.25, pointing to more than 23% downside.

Macquarie is the most bearish among the major brokers, with a neutral rating and target of just over $133. UBS is considerably more optimistic at $181, while Morgan Stanley has a $172 target.

Bell Potter recently retained its hold rating on CSL shares but increased its price target from $120 to $150.

Why has the biotech stock surged?

The catalyst was CSL’s FY26 result, released last week. On the surface, it looked ugly: the company reported a US$2.6 billion net loss after tax.

But there was much more to the number. The loss included US$7.1 billion of pre-tax impairments and US$799 million of restructuring costs, much of which was non-cash. Most impairments related to CSL Vifor intangibles and under-utilised property, plant and equipment.

Investors had already received a warning in May, when CSL flagged around US$5 billion of impairments and cut its FY26 guidance. Excluding these exceptional items, underlying NPATA was US$3.1 billion, down just 2%. Revenue fell 1% to US$15.8 billion but still beat analyst expectations.

For investors, the result therefore represented something potentially more valuable than headline profit: a reset year, cleaner balance sheet and better-than-feared outlook.

CSL Behring remains the standout. Its plasma division generated US$11.4 billion of revenue, with immunoglobulin revenue steady at US$6.2 billion.

CSL Vifor grew revenue 3% to US$2.4 billion, while Seqirus remained under pressure, with revenue down 8% to US$2 billion.

Could the forecast send CSL shares higher?

The bull case centres on FY27. CSL expects underlying NPAT to grow approximately 5%, ahead of consensus expectations of around 2%.

Behring is forecast to deliver mid-single-digit growth, with immunoglobulins growing at a mid-to-high single-digit rate.

The major challenge remains Vifor, where revenue is expected to plunge about 25% as iron generics enter the market.

For CSL shares, the recovery story is clearly gaining momentum. But with the stock already up sharply, investors must decide whether improving fundamentals can justify the renewed optimism.

The post CSL shares have surged 49%: Are brokers finally turning bullish? appeared first on The Motley Fool Australia.

More reading

• Should I buy CSL shares before the end of August?
• Buy, hold, sell: CSL, BHP, Westpac shares
• Could CSL shares really hit $200? Experts reveal their 12-month targets
• ASX 200 healthcare shares soar 9% amid notable FY26 reports from CSL, Pro Medicus
• 3 ASX 200 stocks, including CSL, leaping 15% to 23% in this week’s sliding market

Motley Fool contributor Marc Van Dinther has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended CSL. The Motley Fool Australia has recommended CSL. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

The August earnings season is now coming to a close, with just one day left on Monday to go.

Hundreds of S&P/ASX 200 Index (ASX: XJO) companies have announced their next dividends this month.

We’re helping you keep track of ex-dividend dates with an article every Friday.

Here are the ASX shares going ex-dividend next week.

We’ve listed the dividend amounts investors will receive and when they’ll receive them.

In order to receive a dividend, you must own the ASX share before its ex-dividend date.

ASX shares with ex-dividend dates next week

ASX Share	Ex-Div Date	Dividend	Payday
Pinnacle Investment Management Group Ltd (ASX: PNI)	31 August	31 cents	25 September
Aurizon Holdings Ltd (ASX: AZJ)	31 August	10.5 cents	23 September
Iluka Resources Ltd (ASX: ILU)	31 August	3 cents	24 September
Ansell Ltd (ASX: ANN)	31 August	58.1 cents	17 September
Australian Finance Group Ltd (ASX: AFG)	31 August	4.8 cents	1 October
Carlton Investments Ltd (ASX: CIN)	31 August	73 cents	21 September
Fortescue Ltd (ASX: FMG)	1 September	46 cents	29 September
Codan Ltd (ASX: CDA)	1 September	29 cents	16 September
Endeavour Group Ltd (ASX: EDV)	1 September	1.2 cents	1 October
Bendigo and Adelaide Bank Ltd (ASX: BEN)	1 September	33 cents	30 September
Seek Ltd (ASX: SEK)	2 September	25 cents	1 October
Origin Energy Ltd (ASX: ORG)	2 September	30 cents	2 October
Whitehaven Coal Ltd (ASX: WHC)	2 September	6 cents	15 September
Yancoal Australia Ltd (ASX: YAL)	2 September	7 cents	18 September
Mercury NZ Ltd (ASX: MCY)	2 September	14.1 cents	30 September
Universal Holdings Ltd (ASX: UNI)	2 September	17 cents	24 September
Downer EDI Ltd (ASX: DOW)	2 September	17 cents	1 October
Sonic Healthcare Ltd (ASX: SHL)	2 september	63 cents	17 September
Medibank Private Ltd (ASX: MPL)	2 September	10.9 cents	8 October
PLS Group Ltd (ASX: PLS)	2 September	5 cents	24 September
Monadelphous td (ASX: MND)	2 September	59 cents	24 September
Liberty Financial Group Ltd (ASX: LFG)	2 September	23 cents	21 September
Newmont Corporation CDI (ASX: NEM)	2 September	26 cents	28 September
Amcor Ltd (ASX: AMC)	3 September	92 cents	24 September
BHP Group Ltd (ASX: BHP)	3 September	$1.39	23 September
Qualitas Ltd (ASX: QAL)	3 September	7.7 cents	18 September
NIB Holdings Ltd (ASX: NHF)	3 September	21 cents	7 October
Woodside Energy Group Ltd (ASX: WDS)	3 September	79.5 cents	25 September
Coles Group Ltd (ASX: COL)	3 September	37 cents	22 September
Korvest Ltd (ASX: KOR)	3 September	40 cents	25 September
Schaffer Corporation Ltd (ASX: SFC)	3 September	45 cents	18 September
Symal Group Ltd (ASX: SYL)	3 September	4.9 cents	2 October
Ampol Ltd (ASX: ALD)	4 September	$1.85	30 September
Viva Energy Group Ltd (ASX: VEA)	4 September	7.7 cents	30 September
Aussie Broadband Ltd (ASX: ABB)	4 September	3.6 cents	21 September
Big River Industries Ltd (ASX: BRI)	4 September	2 cents	6 October
Hitech Group Australia Ltd (ASX: HIT)	4 September	4 cents	22 September

The post 37 ASX shares going ex-dividend next week appeared first on The Motley Fool Australia.

More reading

• How much is needed in superannuation for $2,500 in weekly passive income?
• Here are the top 10 ASX 200 shares today
• Buy, hold, sell: Whitehaven, Endeavour, Neuren Pharmaceuticals shares
• Why is the ASX 200 falling to a 4-day low today?
• 7 ASX 200 shares downgraded by brokers this week

Motley Fool contributor Bronwyn Allen has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has positions in and has recommended Aussie Broadband and Pinnacle Investment Management Group. The Motley Fool Australia has positions in and has recommended Amcor Plc, Bendigo And Adelaide Bank, NIB Holdings, and Pinnacle Investment Management Group. The Motley Fool Australia has recommended Ansell, Aussie Broadband, BHP Group, Qualitas, Sonic Healthcare, and Universal Store. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.